Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

United Therapeutics settles patent litigation with Watson Labs; licenses rights to generic Tyvaso

Executive Summary

As part of a patent settlement, United Therapeutics Corp. licensed Watson Laboratories Inc. rights to market a generic version of Tyvaso inhalation solution (treprostinil; marketed for the treatment of pulmonary arterial hypertension) beginning on January 1, 2026. Watson's generics business is part of Teva as Allergan PLC divested the business in July 2015.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Drug Delivery
      • Nasal
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing (Licensing)

Related Companies